Bristol-Myers Squibb (BMY) Acquires Amylin (AMLN) for $5.3 Billion

This week, the pharmaceutical industry consolidated further after Bristol-Myers Squibb (BMY: Charts, News, Offers) announced a $5.3 billion deal to acquire diabetes drug manufacturer Amylin Pharmaceuticals AMLN (AMLN: Charts, News, Offers). New York-based Bristol acquired San Diego, California-based Amylin for $31 per share, a 10% premium to its June 29 closing price. Bristol had made Read the full article...